Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
Canada
/
Pharmaceuticals & Biotech
/
TerrAscend
TSND
TerrAscend
North American Cannabis Will Face Oversupply And Risks Yet Recover
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 2 Analysts
Published
12 Aug 25
Updated
16 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
CA$1.50
8.7% undervalued
intrinsic discount
16 Aug
CA$1.37
Loading
1Y
-29.4%
7D
0%
Author's Valuation
CA$1.5
8.7% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
CA$1.5
8.7% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-342m
312m
2014
2017
2020
2023
2025
2026
2028
Revenue US$254.9m
Earnings US$3.4m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
4.10%
Pharma revenue growth rate
0.58%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.30%
Calculation
US$3.39m
Earnings '28
x
136.50x
PE Ratio '28
=
US$463.28m
Market Cap '28
US$463.28m
Market Cap '28
/
355.01m
No. shares '28
=
US$1.30
Share Price '28
US$1.30
Share Price '28
Discounted to 2025 @ 6.30% p.a.
=
US$1.09
Fair Value '25
US$1.09
Fair Value '25
Converted to CAD @ 1.3814 USD/CAD Exchange Rate
=
CA$1.51
Fair Value '25
